Advances in Combination Therapy for Asthma and COPD
John Wiley & Sons Inc (Verlag)
978-0-470-72702-7 (ISBN)
- Titel z.Zt. nicht lieferbar
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
Jan Lötvall, Professor, Head of Department, EAACI, Secretary-General, co-Editor-in-Chief Respiratory Research, Department of Respiratory Medicine and Allergology, Göteborg University, Göteborg, SWEDEN
Contributors xi Preface xiii
1 Similarities and differences in the pathophysiology of asthma and COPD 1
J. Christian Virchow
1.1 Introduction 1
1.2 Pulmonary function abnormalities in asthma and COPD 3
1.3 Risk factors for asthma and COPD 5
1.4 Cellular inflammation in asthma and COPD 8
1.5 Distribution and consequences of inflammation in asthma and COPD 9
1.6 Patterns of epithelial injury in asthma and COPD 10
1.7 Airway hyperresponsiveness 10
1.8 Beta-receptor blockers 10
1.9 Differential diagnosis of asthma and COPD 11
1.10 Overlap syndrome 12
1.11 Conclusion 12
References 13
2 Glucocorticoids: pharmacology and mechanisms 16
Peter J. Barnes
2.1 Introduction 16
2.2 Chemical structures 16
2.3 The molecular basis of inflammation 17
2.4 Cellular effects of glucocorticoids 19
2.5 Glucocorticoid receptors 20
2.6 Glucocorticoid activation of gene transcription 22
2.7 Suppression of inflammatory genes 23
2.8 Steroid resistance 29
2.9 Interaction with 2-adrenergic receptors 32
2.10 Conclusions 33
References 33
3 Inhaled corticosteroids: clinical effects in asthma and COPD 38
Paul M. O’Byrne and Desmond M. Murphy
3.1 Introduction 38
3.2 Anti-inflammatory activity of corticosteroids 38
3.3 Routes of administration 39
3.4 Absorption and fate of corticosteroids 41
3.5 Currently available inhaled corticosteroids 41
3.6 Efficacy in asthma 43
3.7 Efficacy in COPD 44
3.8 Side effects of ICS 46
3.9 Conclusions 49
References 49
4 LABAs: pharmacology, mechanisms and interaction with anti-inflammatory treatments 53
Gary P. Anderson
4.1 Galenical forms of LABAs: formulations, isomers, enantiomers, diasteriomers and salts 55
4.2 Absolute and functional 2-adrenoceptor selectivity 56
4.3 Cellular organization of receptor clusters: functional structure of the 2-adrenoceptor and mode of signalling 58
4.4 Dimers and oligomers: homo- and heterodimerism/oligoism 60
4.5 Pharmacogenomics of the 2-adrenoceptor and adenylate cyclase polymorphism in relation to LABAs 61
4.6 Understanding the ‘reassertion’ paradox, ‘exosites’ and relative speed of onset: the membrane diffusion microkinetic model of LABA action 61
4.7 Regulation and desensitization 63
4.8 Full versus partial agonism (pharmacological efficacy) 64
4.9 Beta-blockers not LABAs? 67
4.10 Non-receptor-mediated effects? 68
4.11 Biochemical basis of functional antagonism and its critical role in LABA action in disease and exacerbations 68
4.12 Molecular cooperativity between LABAs and steroids 69
4.13 Perspective 73
References 73
5 Long- and ultra-long-acting 2-agonists 81
Mario Cazzola and Maria Gabriella Matera
5.1 Introduction 81
5.2 Long-acting 2-agonists 82
5.3 Novel ultra-long-acting 2-agonists 86
5.4 Conclusion 95
References 95
6 The safety of long-acting beta-agonists and the development of combination therapies for asthma and COPD 102
Victor E. Ortega and Eugene R. Bleecker
6.1 Introduction 102
6.2 Asthma-related mortality and beta-agonist exposure 103
6.3 Long-acting beta-agonists and increased asthma-related mortality 105
6.4 Safety and efficacy of LABA therapy in asthma: retrospective analyses 107
6.5 Efficacy of LABA therapy as a component of combination therapy with ICS for the management of asthma 110
6.6 Scientific basis of the beneficial and adverse effects of beta-agonist therapy: in vitro data and the beta-agonist paradox 113
6.7 Conclusions regarding the safety of LABA therapy as a component of combination therapy with ICS for the management of asthma 114
6.8 Beta-agonist therapy and adverse events in COPD 115
6.9 Safety and efficacy of LABA therapy in the management of COPD: the clinical evidence 116
6.10 Role of LABA therapy as a component of combination therapy with ICS for the management of COPD 117
6.11 Conclusions regarding the safety of LABA therapy as a component of combination therapy for the management of COPD 120
6.12 Pharmacogenetics of LABAs and combination therapy 120
6.13 Safety and efficacy of LABA therapy and the development of combination therapies for the management of asthma and COPD 126
6.14 Summary and future directions 127
Acknowledgement 128
References 128
7 Inhaled combination therapy with glucocorticoids and long-acting 2-agonists in asthma and COPD, current and future perspectives 135
Jan Lötvall
7.1 Pharmacological management guidelines of asthma and COPD 135
7.2 Steroid treatment in asthma 136
7.3 Effects of adding LABA to inhaled glucocorticoids in asthma 137
7.4 Steroid treatment in COPD 140
7.5 Effects of LABAs in COPD 140
7.6 Combination inhalers versus two separate inhalers for inhaled GCS and LABAs 141
7.7 Regular treatment alone versus additional formoterol-containing combinations as reliever therapy 143
7.8 Currently available combination inhalers 145
7.9 Upcoming and alternative combinations of inhaled GCS and LABAs 146
7.10 Future of combined inhalation therapy in respiratory disease 148
References 149
8 Novel anti-inflammatory treatments for asthma and COPD 154
Paul A. Kirkham, Gaetano Caramori, K. Fan Chung and Ian M. Adcock
8.1 Introduction 154
8.2 Current asthma and COPD therapies 158
8.3 The need for new therapies 160
8.4 Improving current therapies 162
8.5 Targeting chemokines and their receptors in asthma and COPD 166
8.6 Targeting T-cell-derived and proinflammatory cytokines in asthma and COPD 169
8.7 Targeting adhesion molecules in asthma and COPD 172
8.8 Growth factor blockers in asthma and COPD 173
8.9 Mucous cells, submucosal glands and mucus production in asthma and COPD 173
8.10 Infections in asthma and COPD 174
8.11 Intracellular signalling pathways 175
8.12 Inhibition of transcription factors in asthma and COPD 178
8.13 Antioxidants in asthma and COPD 181
8.14 Immunomodulation and anti-allergy treatments in asthma and COPD 182
8.15 Conclusions 185
Acknowledgements 186
References 186
9 Novel biologicals alone and in combination in asthma and allergy 203
Sharmilee M. Nyenhuis and William W. Busse
9.1 Introduction 203
9.2 Targets of therapy 204
9.3 Interleukin-4 204
9.4 Interleukin-5 207
9.5 Interleukin-13 211
9.6 Tumor necrosis factor-212
9.7 Immunoglobulin E 215
9.8 DNA vaccines 220
9.9 Future directions 222
9.10 Conclusion 224
References 225
10 Anti-infective treatments in asthma and COPD 232
Jonathan D.R. Macintyre and Sebastian L. Johnston
10.1 Introduction 232
10.2 Current guidelines 234
10.3 Acute exacerbations of asthma 236
10.4 Increased susceptibility to infection in asthmatics 236
10.5 Role of atypical bacteria in asthma 237
10.6 Role of viruses in asthma exacerbations 244
10.7 Anti-infectives in COPD exacerbations 250
10.8 Use of antibiotics in stable COPD 256
10.9 Role of vaccination 257
10.10 Conclusion 259
References 260
11 Long-acting muscarinic antagonists in asthma and COPD 268
M. Diane Lougheed, Josuel Ora and Denis E. O’Donnell
11.1 Introduction 268
11.2 Innervation of the airways 268
11.3 Cholinergic mechanisms in asthma and COPD 270
11.4 Role of long-acting anticholinergic bronchodilators in obstructive lung disease 271
11.5 Summary 287
References 288
12 Phosphodiesterase inhibitors in obstructive lung disease 296
Jan Lötvall and Bo Lundbä ck
12.1 Introduction 296
12.2 Phosphodiesterase enzymes 297
12.3 Different pharmacological agents blocking PDE4 298
12.4 Biological effects of PDE4 inhibition, preclinical information 300
12.5 Clinical effects of PDE4 inhibition in COPD 302
12.6 Effects of PDE4 inhibitors on systemic processes in COPD 304
12.7 Side effects of PDE4 inhibitors 304
12.8 PDE4 inhibitors in COPD management plans 305
12.9 Future prospects with PDE4 inhibitors in obstructive airways disease 305
12.10 Summary 306
References 306
13 Biological therapies in development for COPD 311
J. Morjaria and R. Polosa
13.1 Introduction 311
13.2 Inflammatory cells involved in the pathogenesis of COPD 312
13.3 Cytokines and chemokines in COPD 315
13.4 Development of biological agents in COPD 320
13.5 Conclusions 323
References 323
14 ‘Triple therapy’ in the management of COPD: inhaled steroid, long-acting anticholinergic and long-acting 2-agonist 333
Ronald Dahl
14.1 Introduction 333
14.2 Long-acting inhaled anticholinergic (LAMA) and 2-agonist (LABA) bronchodilators 333
14.3 Treatment strategies for COPD 334
14.4 Inhaled corticosteroids and COPD 334
14.5 Combination treatment with ICS, LAMA and LABA: ‘triple therapy’ 335
14.6 Extracted data from TORCH and UPLIFT studies 337
14.7 Conclusions 340
References 341
Index 343
| Erscheint lt. Verlag | 12.12.2011 |
|---|---|
| Verlagsort | New York |
| Sprache | englisch |
| Maße | 175 x 252 mm |
| Gewicht | 699 g |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Pneumologie |
| ISBN-10 | 0-470-72702-0 / 0470727020 |
| ISBN-13 | 978-0-470-72702-7 / 9780470727027 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
